Global Ventricular Tachycardia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Ventricular Tachycardia treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Armgo Pharma, Audentes Therapeutics , Elex Biotech LLC, Espero BioPharma, Gilead Sciences and others.
A Significant contribution to the Ventricular Tachycardia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Ventricular Tachycardia pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Ventricular Tachycardia condition and increased access to investments is encouraging growth of Ventricular Tachycardia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Ventricular Tachycardia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Ventricular Tachycardia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Ventricular Tachycardia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Ventricular Tachycardia. Further, orphan drug status, fast track designation, grants awarded and other special status for Ventricular Tachycardia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Ventricular Tachycardia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Ventricular Tachycardia Pipeline candidates-
A Significant contribution to the Ventricular Tachycardia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Ventricular Tachycardia pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Ventricular Tachycardia condition and increased access to investments is encouraging growth of Ventricular Tachycardia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Ventricular Tachycardia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Ventricular Tachycardia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Ventricular Tachycardia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Ventricular Tachycardia. Further, orphan drug status, fast track designation, grants awarded and other special status for Ventricular Tachycardia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Ventricular Tachycardia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Ventricular Tachycardia Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Ventricular Tachycardia drugs
- Late phase: Phase 3 and in-approval Ventricular Tachycardia drugs
- Company overview
- Snapshot
- Ventricular Tachycardia therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Ventricular Tachycardia- Disease Overview
2.2 Ventricular Tachycardia- Pipeline Snapshot
2.3 Ventricular Tachycardia- Pipeline Drugs by Phase
2.4 Ventricular Tachycardia- Pipeline Drugs by Company
2.5 Ventricular Tachycardia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Armgo Pharma Ventricular Tachycardia Drug Pipeline, H2- 2019
3.2 Audentes Therapeutics Ventricular Tachycardia Drug Pipeline, H2- 2019
3.3 Elex Biotech LLC Ventricular Tachycardia Drug Pipeline, H2- 2019
3.4 Espero BioPharma Ventricular Tachycardia Drug Pipeline, H2- 2019
3.5 Gilead Sciences Ventricular Tachycardia Drug Pipeline, H2- 2019
3.6 HUYA Bioscience International LLC Ventricular Tachycardia Drug Pipeline, H2- 2019
3.7 InCarda Therapeutics Ventricular Tachycardia Drug Pipeline, H2- 2019
3.8 Milestone Pharmaceuticals Ventricular Tachycardia Drug Pipeline, H2- 2019
3.9 Ono Pharmaceutical Ventricular Tachycardia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Ventricular Tachycardia- Phase 1 Drug Details
4.2 Ventricular Tachycardia- Phase 1 Drug Overview
4.3 Ventricular Tachycardia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Ventricular Tachycardia- Phase 2 Drug Details
5.2 Ventricular Tachycardia- Phase 2 Drug Overview
5.3 Ventricular Tachycardia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Ventricular Tachycardia- Phase 3 Drug Details
6.2 Ventricular Tachycardia- Phase 3 Drug Overview
6.3 Ventricular Tachycardia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Ventricular Tachycardia- Pre-clinical Phase Drug Details
7.2 Ventricular Tachycardia- Pre-clinical Phase Drug Overview
7.3 Ventricular Tachycardia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Ventricular Tachycardia- Disease Overview
2.2 Ventricular Tachycardia- Pipeline Snapshot
2.3 Ventricular Tachycardia- Pipeline Drugs by Phase
2.4 Ventricular Tachycardia- Pipeline Drugs by Company
2.5 Ventricular Tachycardia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Armgo Pharma Ventricular Tachycardia Drug Pipeline, H2- 2019
3.2 Audentes Therapeutics Ventricular Tachycardia Drug Pipeline, H2- 2019
3.3 Elex Biotech LLC Ventricular Tachycardia Drug Pipeline, H2- 2019
3.4 Espero BioPharma Ventricular Tachycardia Drug Pipeline, H2- 2019
3.5 Gilead Sciences Ventricular Tachycardia Drug Pipeline, H2- 2019
3.6 HUYA Bioscience International LLC Ventricular Tachycardia Drug Pipeline, H2- 2019
3.7 InCarda Therapeutics Ventricular Tachycardia Drug Pipeline, H2- 2019
3.8 Milestone Pharmaceuticals Ventricular Tachycardia Drug Pipeline, H2- 2019
3.9 Ono Pharmaceutical Ventricular Tachycardia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Ventricular Tachycardia- Phase 1 Drug Details
4.2 Ventricular Tachycardia- Phase 1 Drug Overview
4.3 Ventricular Tachycardia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Ventricular Tachycardia- Phase 2 Drug Details
5.2 Ventricular Tachycardia- Phase 2 Drug Overview
5.3 Ventricular Tachycardia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Ventricular Tachycardia- Phase 3 Drug Details
6.2 Ventricular Tachycardia- Phase 3 Drug Overview
6.3 Ventricular Tachycardia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Ventricular Tachycardia- Pre-clinical Phase Drug Details
7.2 Ventricular Tachycardia- Pre-clinical Phase Drug Overview
7.3 Ventricular Tachycardia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
